Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

Jayprica: Chronic Lymphocytic Leukemia after prior therapy

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor

Broader topic: Chronic Lymphocytic Leukemia

Source population
Not part of this definition
Disease extent
Not part of this definition
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
    1. class
      who have received at least two prior lines of therapy
      status
      required
    derivation status
    source-attested
    derivation note
    Scoped from the FDA approved indication for Jayprica (pirtobrutinib) (accelerated-approval table). Only dimensions stated in that wording are part of this definition.
    source wording
    Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor

    Study evidence for this setting

    0 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

    No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.

    Source relationships and population-mapping limitations
    bindings
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice